Research Analysts’ Recent Ratings Changes for Disc Medicine (IRON)

Posted by James Quigley on Feb 7th, 2025

A number of research firms have changed their ratings and price targets for Disc Medicine (NASDAQ: IRON):

1/24/2025 – Disc Medicine had its price target raised by analysts at Stifel Nicolaus from $90.00 to $94.00. They now have a “buy” rating on the stock.
1/22/2025 – Disc Medicine had its price target raised by analysts at Scotiabank from $70.00 to $73.00. They now have a “sector outperform” rating on the stock.
1/21/2025 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $90.00 price target on the stock, up previously from $83.00.
1/21/2025 – Disc Medicine had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $118.00 price target on the stock.
1/10/2025 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $83.00 price target on the stock.
12/10/2024 – Disc Medicine had its price target raised by analysts at Stifel Nicolaus from $79.00 to $90.00. They now have a “buy” rating on the stock.
12/9/2024 – Disc Medicine had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $83.00 price target on the stock.
12/9/2024 – Disc Medicine had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $118.00 price target on the stock.

Disc Medicine Price Performance

Shares of IRON stock traded down $0.86 on Friday, hitting $55.43. 126,825 shares of the stock traded hands, compared to its average volume of 437,682. The company has a market capitalization of $1.65 billion, a PE ratio of -13.93 and a beta of 0.74. The company’s fifty day moving average is $61.33 and its 200 day moving average is $54.32. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15. As a group, equities research analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insiders Place Their Bets

In related news, CEO John D. Quisel sold 12,791 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. This represents a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William Richard White sold 1,957 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $64.63, for a total value of $126,480.91. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 85,921 shares of company stock worth $5,389,978. Corporate insiders own 4.24% of the company’s stock.

Institutional Trading of Disc Medicine

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company’s stock valued at $400,000 after acquiring an additional 593 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Disc Medicine by 2.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after buying an additional 771 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Disc Medicine by 19.5% during the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after buying an additional 793 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Disc Medicine by 5.7% during the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company’s stock worth $1,841,000 after buying an additional 1,553 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.